Results 131 to 140 of about 25,935 (265)

Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells

Discover Oncology
Purpose This study aims to investigate the effect of Niraparib in combination with an Anti-GD2 Antibody on osteosarcoma cells. Methods Scratch test was utilized to assess cell migration capacity, while the Transwell experiment was utilized to evaluate ...
Chen Wenyao, Ma Shuai, Fan Yifeng, Li Xinzhi, Que Xiangyong   +4 more
doaj   +1 more source

IMMU-15. PHASE I TRIAL OF GD2.CART-CELLS AUGMENTED WITH A CONSTITUTIVELY ACTIVE INTERLEUKIN-7 RECEPTOR (C7R) FOR TREATMENT OF HIGH-GRADE PEDIATRIC CNS TUMORS [PDF]

, 2023
Frank Y. Lin, Austin J. Stuckert, Candise Tat, Karen Moeller, Mark D. White, Lucia Ruggieri, Huimin Zhang, Holly Lindsay, Patricia Baxter, Fatema Malbari, Guillermo Aldave, Murali Chintagumpala, D. Williams Parsons, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney, Bilal Omer   +16 more
openalex   +1 more source

Supplementary Figure S1 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells

, 2023
Hung C. Tran, Zesheng Wan, Michael A. Sheard, Jianping Sun, Jeremy R. Jackson, Jemily Malvar, Yibing Xu, Larry Wang, Richard Sposto, Eugene S. Kim, Shahab Asgharzadeh, Robert C. Seeger   +11 more
openalex   +1 more source

Faculty Opinions recommendation of NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma.

, 2021
David T. Teachey
openalex   +2 more sources

Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro.

PLoS ONE
Cancer immunotherapy, particularly T cell-based therapies, is considered to have strong potential for treating various types of cancer. A promising approach that has emerged is the use of γδ T cell-based strategies for cancer treatment. Neuroblastoma (NB)
Kuntida Kitidee, Sumet Amonyingcharoen, Sarinthip Preedagasamzin, Korakot Atjanasuppat, Piamsiri Sawaisorn, Pornprapa Srimorkun, Sawang Petvises, Wanpen Chaicumpa, Suparerk Borwornpinyo, Usanarat Anurathapan, Suradej Hongeng   +10 more
doaj   +1 more source

Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors [PDF]

, 2018
Giulia Golinelli, Giulia Grisendi, Malvina Prapa, Marco Bestagno, Carlotta Spano, Filippo Rossignoli, Franco Bambi, Iacopo Sardi, Monica Cellini, Edwin M. Horwitz, Alberto Feletti, Giacomo Pavesi, Massimo Dominici   +12 more
openalex   +1 more source

GD2 Antibody [PDF]

, 2020
openaire   +1 more source

A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor

Biomarker Research
Osteosarcoma is the commonest malignant bone tumour in children, with a poor prognosis due to limited treatment options. Antibody–drug conjugates (ADCs) offer targeted therapeutic potential but are limited by the low expression of specific antigens like ...
Jing Shan, Zicheng Lin, Harunor Rashid, Peng Huang, Lei Qiang, Yihao Liu, Guanlu Shen, Yuchen Li, Jiaming Cui, Zhi Su, Hanbo Wang, Bixuan Cao, Cheng Zhou, Veysel Kayser, Bo Ning   +14 more
doaj   +1 more source

Intermediary filament and GD2-expression in astrocytic tumors

, 2008
By means of immunhistochemical markers the expression of glial fibrillary acidic protein, vimentin and glykosphingolipid GD2 is investigated in 28 astrocytic tumors grading WHO II-IV. Statistically, there is found a high correlation in the cytoplasmatic expression of GFAP/GD2 as well as Vimentin/GD2 and GFAP/Vimentin.The semiquantitatively strongest ...
openaire   +3 more sources

ACTIVATION OF HUMAN EFFECTOR CELLS BY A TUMOR REACTIVE RECOMBINANT ANTI-GANGLIOSIDE GD2 INTERLEUKIN-2 FUSION PROTEIN

, 1996
J A Hank, Jean E. Surfus, Jing Gan, P Jaeger, Stephen D. Gillies, R A Reisfeld, Paul M. Sondel   +6 more
openalex   +1 more source